All In MedTech

Device Trial Radar · NCT05485935

A Confirmatory Study Confirming Performance of a New Intermittent Catheter

A Confirmatory, Multi-centre, Randomized, Open Label, Controlled Study Confirming Performance of a Single-use Intermittent Micro-holes Zone Catheter in a Population of Adult Male Intermittent Catheter Users.

Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Aug 20, 2022

Primary completion

Jan 3, 2023

Study completion Jan 3, 2023

Sponsor

Lead sponsor
Coloplast A/SNot on our public-company list
Sponsor type
Industry
First posted
Aug 3, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-centre, randomized, controlled crossover design. The total study duration for the individual subject was approximately 9 weeks. The study consisted of four study visits (V0-V3) and two 4-week test periods at home (T1 and T2). Visit 0 and 1 was performed on the same day if subjects allowed. One population included all enrolled subjects who took part in the two test periods in a home setting only (T1 and T2). This constituted the Full Analysis Set (FAS) 1 (N=73)where only endpoints related to dipstick hematuria, catheter perception and quality of life were assessed. A subset of subjects from the FAS1 also took part in two clinic visits (V2 and V3) where endpoints related to bladder emptying and discomfort were assessed. One visit took place in between the two test periods at home (V2) and the other visit took place after the last test period at home (V3) which was also the termination visit. This subset is termed the FAS 2 (N=49).

Conditions

  • Urinary Retention

Interventions

  • Investigational device - intermittent catheter with micro-hole zoneDevice

    Intermittent male catheter with micro-hole zone for urinary drainage

  • Comparator - standard intermittent catheterDevice

    SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Residual Urine at 1st Flow Stop (HCP-led Catheterization) i.e., Total Catheterisation Volume Minus Volume at 1st Flow-stop, Both Derived From a Catheterisation ProfileTime frame: Immediately after the procedure/catheterization, at second and third clinic visit following 4 weeks of home catheterization
  2. Number of Flow-stop Episodes (HCP-led Catheterization)Time frame: Immediately after catheterisation, at second and third clinic visit following 4 weeks of home catheterization

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark

  • Sanos Clinic

    Gandrup, North Denmark, Denmark

  • Hopital Claude Huriez

    Lille, France

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.